Saltar al contenido principal
Elsevier

Advances in DNA and mRNA-Based strategies for Cancer Immunotherapy: Part B

  • 1 Edición, Volumen 166 - 30 de julio de 2025
  • Última edición
  • Editores: Arun Kumar Singh, Kenneth Murphy, Neeraj Mishra, Frederick Alt, Sumel Ashique, Pranav Kumar Prabhakar
  • Idioma: Inglés

Advances in Immunology, Volume 166, the latest release in a long-established and highly respected publication, presents current developments and comprehensive reviews in immuno… Leer más

Descripción

Advances in Immunology, Volume 166, the latest release in a long-established and highly respected publication, presents current developments and comprehensive reviews in immunology.

Puntos claves

  • Presents current developments and comprehensive reviews in immunology
  • Provides the latest in a longstanding and respected serial on the subject matter
  • Focuses on recent advances in the field of immunology

De interès para

Immunologists and infectious disease specialists, cell biologists and hematologists

Índice

1. Harnessing the immune system: Insights into cancer vaccines

Sushree Subhadra Acharya, Subhasmita Bhal, Biswajit Das, and

Chanakya Nath Kundu

2. Lipid nanoparticle mediated mRNA delivery in cancer immunotherapy

Gyati Shilakari Asthana, Saptarshee Bhattacharjee, Jitendra Kumar, Soyal Sayyed, Amulya Jindal, Pankaj Kumar, Abhijeet Chinchane, Atreyee Bhattacharyya, Roshani Jaiswal,

Sagar Kulkarni, Shubham Gajdhane, Jitender Madan, and Abhay Asthana

3. Nanoparticles for mRNA-based cancer immunotherapy

Rakesh Pahwa, Gulshan Sharma, Rohil Panwar, and Neeraj Mishra

4. B-cell editing: An emerging alternative of precision oncotherapy

Pritha Roy Choudhury, Mohona Chakravarti, Saptak Banerjee,

Rathindranath Baral, and Anamika Bose

5. Personalized precision: Revolutionizing cancer treatment with mRNA-based vaccines in melanoma therapy

Krishnendu Adhikary, Abhik Paul, Ayush Madan, Anas Islam, Sumel Ashique,
and Mohhammad Ramzan

6. Revolutionizing cancer treatment: Exploring novel immunotherapeutics, checkpoints, bispecifics, and vaccines in development

Anas Islam, Vijay Singh, Pooja S. Murkute, Sumel Ashique,

Shriyansh Srivastava, Mohammad Yousuf Ansari, and Sabina Yasmin

7. Recent progress, challenges (stability and in vivo distribution), and opportunities of DNA & mRNA vaccine in cancer immunotherapy

Monika Kaushik, Prathap Madeswaraguptha, Murugesan Vanangamudi, Vijayaraj Surendran, Sumel Ashique, Anas Islam, Naheed Mojgani, and Afzal Hussain

Detalles del producto

  • Edición: 1
  • Última edición
  • Volumen: 166
  • Publicado: 15 de agosto de 2025
  • Idioma: Inglés

Sobre los editores

AS

Arun Kumar Singh

Arun Kumar Singh is an Assistant Professor in the Department of Pharmacy at University School of Pharmaceutical Sciences, Rayat Bahra University V.P.O. Sahauran, India. He completed his M.Pharm in Pharmaceutics from Galgotias University, Greater Noida. His research interests include nano-formulation, blockchain, IoT, machine learning, artificial intelligence, big data analytics, cancer biology, and neuroscience. He has contributed to academic books and book chapters and has published review articles in the areas of pharmaceutical sciences and healthcare technology. His work focuses on interdisciplinary approaches integrating pharmaceutical research with emerging digital and computational technologies.
Afiliaciones y experiencia
Assistant Professor, University School of Pharmaceutical Sciences, Rayat Bahra University V.P.O. Sahauran, Tehsil Kharar, Distt. Mohali, Punjab, India

KM

Kenneth Murphy

Kenneth M. Murphy works in Washington University School of Medecine, USA.
Afiliaciones y experiencia
Washington University School of Medecine, USA

NM

Neeraj Mishra

Dr. Neeraj Mishra is Professor and Head of the Department of Pharmaceutics at the Amity Institute of Pharmacy, Gwalior. He has over 20 years of teaching and research experience in pharmaceutics, with particular expertise in novel drug delivery systems, localized and targeted drug delivery, and nanocarrier-based therapeutics for disease. His formulations and controlled delivery approaches are aimed at improving therapeutic outcomes. Dr. Mishra has supervised postgraduate and doctoral research scholars, has contributed widely to academic literature through research publications, books, and book chapters with leading international publishers. He has won several awards including Outstanding Scientist Award, and Distinguished Professor Award. He is associated with innovation in pharmaceutical sciences through patented research contributions. Over the course of his career, he has received several academic and scientific recognitions for his contributions to teaching, and research. He has been recognized internationally for his research impact and scholarly contributions.

Afiliaciones y experiencia
Professor and Head of Department, Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Gwalior, Madhya Pradesh, India

FA

Frederick Alt

Frederick W. Alt is a Howard Hughes Medical Institute (HHMI) Investigator and Director of the Program in Cellular and Molecular Medicine (PCMM) at Boston Children's Hospital (BCH). He is the Charles A. Janeway Professor of Pediatrics and Professor of Genetics at Harvard Medical School. He works on elucidating mechanisms that generate antigen receptor diversity and, more generally, on mechanisms that generate and suppress genomic instability in mammalian cells, with a focus on the immune and nervous systems. Recently, his group has developed senstive genome-wide approaches to identify mechanisms of DNA breaks and rearrangements in normal and cancer cells. He has been elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the European Molecular Biology Organization. His awards include the Albert Szent-Gyorgyi Prize for Progress in Cancer Research, the Novartis Prize for Basic Immunology, the Lewis S. Rosensteil Prize for Distinugished work in Biomedical Sciences, the Paul Berg and Arthur Kornberg Lifetime Achievement Award in Biomedical Sciences, and the William Silan Lifetime Achievement Award in Mentoring from Harvard Medical School.
Afiliaciones y experiencia
Professor of Pediatrics and Professor of Genetics, Harvard Medical School, Boston, MA, USA

SA

Sumel Ashique

Dr. Sumel Ashique has been working as an assistant professor at the Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, West Bengal, India. He has 5 years of teaching experience. He has achieved 100+ publications in international and national accredited reputed journals. He has expertise in drug delivery, nanotechnology, and targeted treatment strategies. Recently, he was honored to be in the World’s Top 2% Scientists by prestigious Stanford University, CA, United States, and Elsevier in 2025.

Afiliaciones y experiencia
Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, Kolkata, West Bengal, India

PP

Pranav Kumar Prabhakar

Dr. Pranav Kumar Prabhakar is Professor and Head of the Department of Biotechnology, School of Engineering and Technology, Nagaland University, Meriema, Kohima, Nagaland, India. His research focuses on elucidating molecular mechanisms involved in metabolic disorders, particularly diabetes, including strategies for oral insulin delivery and the use of natural products to mimic signaling pathways. He is a member of the Royal Society of Chemistry and the Asia-Pacific Chemical, Biological & Environmental Engineering Society. Dr. Prabhakar serves on the editorial boards of, and acts as a reviewer for, several national and international scientific journals. He has published extensively in his field and has contributed to numerous books and book chapters. He has also presented his research at scientific meetings and conferences.

Afiliaciones y experiencia
Professor and Head, Department of Biotechnology, School of Engineering and Technology, Nagaland University, Meriema, Kohima, Nagaland, India

Ver libro en ScienceDirect

Lee Advances in DNA and mRNA-Based strategies for Cancer Immunotherapy: Part B en ScienceDirect